Eversept Partners’s Novo Nordisk NVO Stock Holding History

Eversept Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.11M	Buy	+169,227	New	+$7.27M	0.42%	57
2025 Q4	–	Sell	-217,708	Closed	-$12.1M	–	116
2025 Q3	$12.1M	Buy	+217,708	New	+$12.7M	0.83%	29
2024 Q3	–	Sell	-146,956	Closed	-$21M	–	77
2024 Q2	$21M	Buy	146,956 +84,612	+136%	+$11.2M	1.44%	18
2024 Q1	$8M	Buy	+62,344	New	+$7.42M	0.53%	34

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Eversept Partners's NVO Position: Q2 2026 in Review

Eversept Partners opened a new position in Novo Nordisk (NVO) in Q2 2026: 169,227 shares worth $8.11M. The stake represents 0.42% of the portfolio and ranks #57 among its holdings. This is a return to the name: Eversept Partners previously reported a position in NVO as recently as Q3 2025.

Eversept Partners first reported a position in NVO in Q1 2024 and has held it in 4 quarters since. The position peaked at $21M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Eversept Partners held 169,227 shares of Novo Nordisk worth $8.11M as of Q2 2026.
Novo Nordisk was a new Eversept Partners position in Q2 2026.
Novo Nordisk made up 0.42% of Eversept Partners's portfolio in Q2 2026, its #57 holding.
Eversept Partners first reported a position in Novo Nordisk in Q1 2024 and has held it in 4 quarters since.
Eversept Partners's Novo Nordisk position peaked at $21M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.